Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ABAT | P80404 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | XBP1 | P17861 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4392250 | 0.94 | KMT2A (0.54) | KMT2ALMNAALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL4396662 | 0.94 | KMT2A (0.54) | KMT2ALMNAALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL1258720 | 0.93 | ALDH1A1 (0.53) | KMT2ALMNAALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL31300043 | 0.86 | CYP1A2 (0.58) | KMT2ALMNAALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL15284035 | 0.85 | SMN1; SMN2 (0.58) | KMT2ALMNAALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL14515852 | 0.85 | LMNA (0.64) | KMT2ALMNAALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL31300041 | 0.85 | ALDH1A1 (0.59) | LMNAALDH1A1RAB9ASMN1; SMN2GAA | |
| SCHEMBL5668241 | 0.84 | CA1 (0.50) | KMT2ALMNASMN1; SMN2NPSR1GAA | |
| SCHEMBL2425405 | 0.84 | ALDH1A1 (0.55) | KMT2ALMNAALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL1258488 | 0.82 | ABAT (0.64) | KMT2ALMNAALDH1A1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025024883-A1 | NOVEL BROAD SPECTRUM ANTIVIRAL AND ANTIMICROBIAL PEPTIDE MIMICS | NEWSOUTH INNOVATIONS PTY LIMITED (AU) | 2025-02-06 | — | — | WO | disclosed |
| EP-1300401-B1 | THIAZOLE DERIVATIVES FOR USE AS ANTIINFLAMMATORIES | DAINIPPON SUMITOMO PHARMA CO (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-7396842-B2 | Five-membered cyclic compounds | DIANIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-08 | — | — | US | disclosed |
| US-7396842-B2 | Five-membered cyclic compounds | DIANIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-08 | — | — | US | disclosed |
| EP-1669070-A2 | 2-imino-thiazolidine and -oxazolidine derivatives for use as antiinflammatory agents | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-06-14 | — | — | EP | disclosed |
| US-20050222226-A1 | Five-membered cyclic compounds | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED | 2005-10-06 | — | — | US | disclosed |
| US-6919361-B2 | Five-membered-ring compound | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-07-19 | — | — | US | disclosed |
| US-20040072827-A1 | Five-membered-ring compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1300401-A1 | FIVE-MEMBERED-RING COMPOUND | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072827-A1 | Five-membered-ring compound | EPX, IL5, CCR9 | KMT2A 2344/4885LMNA 4315/4885ALDH1A1 3257/4885 |
| US-20050222226-A1 | Five-membered cyclic compounds | EPX, CCL11, CCR9 | KMT2A 2559/4885LMNA 3956/4885ALDH1A1 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.